Effective Lung Cancer Screening

February 2015, Vol 6, No 1

Categories:

Lung Cancer

Related Articles
Filling an Educational Void: AONN+ Announces Cancer Advocacy & Patient Education (CAPE) Lung Cancer Initiative
Cheryl Bellomo, MSN, RN, OCN, ONN-CG, Danelle Johnston, MSN, RN, ONN-CG, OCN, Amy Jo Pixley, MSN, RN, OCN, ONN-CG
|
Best Practices in Lung Cancer – November 2019 Vol 10 – Filling an Educational Void
Physical, Psychological, Social, and Spiritual Well-being of Patients and Caregivers Following Lung Cancer Diagnosis: A Scoping Review
Cheryl Bellomo, MSN, RN, OCN, ONN-CG, Amy Jo Pixley, MSN, RN, OCN, ONN-CG, Danelle Johnston, MSN, RN, ONN-CG, OCN
|
August 2019 Vol 10, No 8
Lorbrena (Lorlatinib) Approved for the Treatment of Metastatic Non–Small-Cell Lung Cancer with ALK Mutation
Loretta Fala
|
2019 Fourth Annual Oncology Guide to New FDA Approvals
Lung and bronchus cancer, the second most common form of cancer, accounts for 13.5% of all new cancer cases in the United States. In 2018 alone, lung cancer was newly diagnosed in 234,030 individuals and accounted for 154,050 deaths. In fact, lung cancer is the leading cause of cancer-related mortality in men and women, and is responsible for more than 25% of all cancer deaths. The 5-year survival rate for patients whose lung cancer has spread regionally (to regional lymph nodes) is 29.7%, but that survival rate is only 4.7% for patients with distant metastases.
Last modified: March 16, 2017

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code